PA8575501A1 - Nueva combinacion - Google Patents

Nueva combinacion

Info

Publication number
PA8575501A1
PA8575501A1 PA20038575501A PA8575501A PA8575501A1 PA 8575501 A1 PA8575501 A1 PA 8575501A1 PA 20038575501 A PA20038575501 A PA 20038575501A PA 8575501 A PA8575501 A PA 8575501A PA 8575501 A1 PA8575501 A1 PA 8575501A1
Authority
PA
Panama
Prior art keywords
new combination
phosphodesterase
antigonist
gmpc
pde5
Prior art date
Application number
PA20038575501A
Other languages
English (en)
Spanish (es)
Inventor
Bernadette Hughes
David Nathan Abraham Fox
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8575501A1 publication Critical patent/PA8575501A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PA20038575501A 2002-06-26 2003-06-13 Nueva combinacion PA8575501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination

Publications (1)

Publication Number Publication Date
PA8575501A1 true PA8575501A1 (es) 2003-12-30

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038575501A PA8575501A1 (es) 2002-06-26 2003-06-13 Nueva combinacion

Country Status (20)

Country Link
EP (1) EP1524996A2 (https=)
JP (1) JP2005531627A (https=)
KR (1) KR20050013156A (https=)
CN (1) CN1662257A (https=)
AR (1) AR040337A1 (https=)
AU (1) AU2003242895A1 (https=)
BR (1) BR0312030A (https=)
CA (1) CA2491002A1 (https=)
GB (1) GB0214784D0 (https=)
GT (1) GT200300124A (https=)
MX (1) MXPA04012569A (https=)
NO (1) NO20050400L (https=)
PA (1) PA8575501A1 (https=)
PE (1) PE20040868A1 (https=)
PL (1) PL375079A1 (https=)
RU (1) RU2004136276A (https=)
TW (1) TW200404546A (https=)
UY (1) UY27863A1 (https=)
WO (1) WO2004002461A2 (https=)
ZA (1) ZA200409532B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
EP2433555A3 (en) * 2002-07-26 2013-01-16 Olympus Corporation Image processing system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
ES2376628T3 (es) 2005-06-10 2012-03-15 Dong-A Pharmaceutical Co., Ltd. Agente para la prevención y el tratamiento de las enfermedades hep�?ticas que contiene un dirivado pirazolopirimidina.
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
EP1940389A2 (en) * 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2345763C1 (ru) * 2007-04-26 2009-02-10 ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6362178B1 (en) * 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Also Published As

Publication number Publication date
ZA200409532B (en) 2006-06-28
CN1662257A (zh) 2005-08-31
PE20040868A1 (es) 2004-11-25
MXPA04012569A (es) 2005-04-19
AU2003242895A1 (en) 2004-01-19
RU2004136276A (ru) 2005-09-10
KR20050013156A (ko) 2005-02-02
JP2005531627A (ja) 2005-10-20
BR0312030A (pt) 2005-03-22
AR040337A1 (es) 2005-03-30
GT200300124A (es) 2004-03-17
NO20050400L (no) 2005-03-29
WO2004002461A3 (en) 2004-05-13
GB0214784D0 (en) 2002-08-07
EP1524996A2 (en) 2005-04-27
PL375079A1 (en) 2005-11-14
UY27863A1 (es) 2003-12-31
WO2004002461A2 (en) 2004-01-08
TW200404546A (en) 2004-04-01
CA2491002A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
BR0108485A (pt) Derivados do antiviral azaindol
PA8575501A1 (es) Nueva combinacion
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
DE60310131D1 (de) Vorrichtung zur energieerzeugung von abgaswärme
IS6689A (is) Forlyf af fosfónat-kirna hliðstæðum og aðferð tilað velja og búa þær til
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
IL162728A0 (en) Methods of inducing differentiationin stem cells, methods of generating tissue using scaffold matrices derived from micro-organs and stem c
PT1344429E (pt) Dispositivo de iluminação
MA29154B1 (fr) Promedicament amide de gemcitabine, compositions et utilisations associees
PA8574201A1 (es) Nueva combinacion
MY209504A (en) Led lighting device having additional function
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
ECSP045466A (es) Inhibidores de la peptido-desformilasa
PY0223362A (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
DE602004009824D1 (de) Analyse von massenspektraldaten in den ruhigen gebieten
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
UY26975A1 (es) Inhibición de la dependencia de células tumorales del factor de crecimiento.
TW200605885A (en) Multicyclic lonidamine analogs
DOP2003000649A (es) Nueva combinacion
DOP2003000645A (es) Nueva combinacion
NO20044186L (no) Peptid-deformylaseinhibitorer
UY26893A1 (es) Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
CY1106689T1 (el) Θεραπεια της δυσκινησιας με 2,3-βενζοδιαζεπινες